Constructive Bio’s 2025 achievements in non-canonical amino acid (ncAA) incorporation include expanded platform capabilities, new partnerships, and recognition from Nature…
Constructive Bio and RxCelerate have partnered to combine programmable biology and ncAA-enabled protein engineering with drug design and development capabilities,…
Constructive Bio has secured an exclusive licence for tRNA display technology, enabling directed integration of non-canonical amino acids (ncAAs) and…
Constructive Bio secured $58 million in Series A financing, bringing total funding to $75 million, to scale its BioForge fermentation…
Engineering the future of biology with revolutionary genome synthesis and expanded genetic code technology.
QUICK LINKS
JOIN OUR NEWSLETTER
© 2026 Constructive Bio. All rights reserved.